{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T03:40:13Z","timestamp":1761104413952,"version":"build-2065373602"},"reference-count":18,"publisher":"Wiley","issue":"7","license":[{"start":{"date-parts":[[2016,6,30]],"date-time":"2016-06-30T00:00:00Z","timestamp":1467244800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["accpjournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Pharmacotherapy"],"published-print":{"date-parts":[[2016,7]]},"abstract":"<jats:sec><jats:title>Study Objective<\/jats:title><jats:p>To determine whether extended\u2010infusion carboplatin, initiated at approximately the eighth cumulative carboplatin cycle and prior to development of carboplatin hypersensitivity, reduces the incidence of carboplatin hypersensitivity reactions in patients with ovarian, fallopian tube, or peritoneal cancer.<\/jats:p><\/jats:sec><jats:sec><jats:title>Design<\/jats:title><jats:p>Retrospective chart review.<\/jats:p><\/jats:sec><jats:sec><jats:title>Setting<\/jats:title><jats:p>Large integrated health system.<\/jats:p><\/jats:sec><jats:sec><jats:title>Patients<\/jats:title><jats:p>A total of 326 patients with ovarian, fallopian tube, or primary peritoneal cancer who received at least eight cumulative cycles of carboplatin between January 2007 and September 2014 were included. Of these, 161 patients received all doses of carboplatin infused over 30 or 60 minutes (standard\u2010infusion group [total of 1317 carboplatin cycles]), and 165 patients received the 3\u2010hour extended infusion of carboplatin administered at approximately the eighth cumulative cycle and prior to development of a hypersensitivity reaction (extended\u2010infusion group [total of 1527 carboplatin cycles]).<\/jats:p><\/jats:sec><jats:sec><jats:title>Measurements and Main Results<\/jats:title><jats:p>Baseline characteristics were similar between the groups, except significantly more patients in the extended\u2010infusion group received triple premedication therapy prior to infusion (p&lt;0.001). Hypersensitivity reactions occurred in 64 patients (40%) who received standard\u2010infusion carboplatin and 40 patients (24.2%) who received extended\u2010infusion carboplatin (p=0.0027). The median cycle of hypersensitivity reaction development did not differ significantly between the groups: 9 cycles in patients who received standard\u2010infusion versus 11 cycles in patients who received extended\u2010infusion carboplatin (p=0.06). Through regression analysis, the premedication regimen received prior to carboplatin infusion was the only variable significantly associated with hypersensitivity reactions (odds ratio 0.59, 95% confidence interval 0.36\u20130.97, p=0.038).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Patients who received extended\u2010infusion carboplatin experienced a lower incidence of hypersensitivity reactions than patients who received standard\u2010infusion carboplatin, which may be attributed to the triple premedication regimen received more frequently in patients in the extended\u2010infusion group.<\/jats:p><\/jats:sec>","DOI":"10.1002\/phar.1769","type":"journal-article","created":{"date-parts":[[2016,5,19]],"date-time":"2016-05-19T22:27:10Z","timestamp":1463696830000},"page":"723-730","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Effect of Prophylactic Extended\u2010Infusion Carboplatin on Incidence of Hypersensitivity Reactions in Patients with Ovarian, Fallopian Tube, or Peritoneal Carcinomas"],"prefix":"10.1002","volume":"36","author":[{"given":"Amy L.","family":"Pasternak","sequence":"first","affiliation":[{"name":"Department of Pharmacy Cleveland Clinic Hillcrest Hospital Mayfield Heights Ohio"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicholas A.","family":"Link","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Cleveland Clinic Hillcrest Hospital Mayfield Heights Ohio"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carolyn M.","family":"Richardson","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Cleveland Clinic Hillcrest Hospital Mayfield Heights Ohio"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter G.","family":"Rose","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology Cleveland Clinic Cleveland Ohio"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2016,6,30]]},"reference":[{"key":"e_1_2_7_2_1","unstructured":"NCCNClinical Practice Guidelines in Oncology: Ovarian Cancer including Fallopian Tube Cancer and Primary Peritoneal Cancer. Fort Washington (PA): National Comprehensive Cancer Network Inc.;2015Feb. 91 p. Report No: Version 1.2015"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1048-891x.2005.14401.x"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1525-1438.2007.01063.x"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2006.04.002"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0090-8258(03)00155-0"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2009.10.070"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdr441"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2001.19.12.3126"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.05.539"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/IGC.0b013e3181a418ff"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2008.02.044"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2004.08.002"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.21168"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00432-003-0501-3"},{"key":"e_1_2_7_16_1","unstructured":"Common Terminology Criteria for Adverse Events. National Cancer Institute and National Institutes of Health.2009May; 80 p. Version 4.0."},{"key":"e_1_2_7_17_1","unstructured":"Common Terminology Criteria for Adverse Events. National Cancer Institute and National Institutes of Health.2003March; 72 p. Version 3.0."},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1002\/phar.1739"},{"key":"e_1_2_7_19_1","unstructured":"O'CearbhaillR. Standard infusion carboplatin versus prophylactic extended infusion carboplatin in the treatment of patients with recurrent ovary fallopian tube and primary peritoneal cancer. In: ClinicalTrials.gov. Bethesda MD: National Library of Medicine. Available fromhttps:\/\/clinicaltrials.gov\/ct2\/show\/NCT01248962?term=01248962&rank=1. Accessed May 1 2015."}],"container-title":["Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fphar.1769","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/phar.1769","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T13:53:42Z","timestamp":1761054822000},"score":1,"resource":{"primary":{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/10.1002\/phar.1769"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,6,30]]},"references-count":18,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2016,7]]}},"alternative-id":["10.1002\/phar.1769"],"URL":"https:\/\/doi.org\/10.1002\/phar.1769","archive":["Portico"],"relation":{},"ISSN":["0277-0008","1875-9114"],"issn-type":[{"type":"print","value":"0277-0008"},{"type":"electronic","value":"1875-9114"}],"subject":[],"published":{"date-parts":[[2016,6,30]]},"assertion":[{"value":"2016-06-30","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}